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ABSTRACT:
Neutrophil gelatinase-associated lipocalin (NGAL, a.k.a Lnc2) is a member 
of the lipocalin family which has diverse roles including stabilizing matrix 
metalloproteinase-9 from auto-degradation and as siderocalins which are important 
in the transport of iron. NGAL also has important biological functions involved in 
immunity and inflammation as well as responses to kidney damage. NGAL expression 
has also been associated with certain neoplasia and is important in the metastasis of 
breast cancer. Many advanced cancer patients have elevated levels of NGAL in their 
urine and it has been proposed that NGAL may be a prognostic indicator for certain 
cancers (e.g. breast, brain, and others). NGAL expression is detected in response 
to various chemotherapeutic drugs including doxorubicin and docetaxel. We were 
interested in the roles of NGAL expression in cancer and whether it is associated 
with chemotherapeutic drug resistance. In the present study, we investigated 
whether increased NGAL expression led to resistance to the chemotherapeutic drug 
doxorubicin in normal breast epithelial cells (MCF-10A), breast cancer cells (MCF-
7), and colorectal cancer cells (HT-29). We infected the various cell lines with a 
retrovirus encoding NGAL which we constructed. Increased NGAL expression was 
readily detected in the NGAL-infected cells but not the empty vector-infected cells. 
However, increased NGAL expression did not alter the sensitivity of the cells to the 
chemotherapeutic drug doxorubicin. Thus, although NGAL expression is often detected 
after chemotherapeutic drug treatment, it by itself, does not lead to doxorubicin 
resistance. 
INTRODUCTION  
Identifying the pathways activated and critical for 
cancer initiation and subsequent spread (invasion and 
metastasis) are essential for improved cancer therapy. Also, 
it is essential to understand how cells develop resistance to 
various therapeutic approaches and whether the resistance 
results from intrinsic or extrinsic events. Over the past 35 
years, many genes have been identified which can cause 
or contribute to cancer [1,2]. These include two major 
classes of genes, the oncogenes and the tumor suppressor 
genes [3,4]. Moreover, microRNAs (miRNAs) and 
epigenetic modifications have been shown to be important 
in regulating cancer progression [5-8]. In some cases, 
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the genetic culprit involved in a particular cancer may 
be known (e.g., BCR-ABL in chronic myeloid leukemia 
[9,10]. However, in most cases, there are multiple genetic 
and epigenetic events occuring which interact and develop 
into a cancer cell capable of becoming metastatic and/
or drug resistant. In addition, there are other important 
contributions by the tumor microenvironment which aid 
in the progression of the cancer as well as resistance to 
various therapeutic approaches and the survival of cancer 
initiating cells [11-13]. 
One factor which may be important for cancer 
survival and metastasis is neutrophil gelatinase-associated 
lipocalin (NGAL). One of the genomic responses 
to common cancer treatments such as radiation and 
chemotherapy is the induction of NGAL expression [14-
19]. NGAL may act to stabilize MMP-9 and increase 
its ability to degrade the extracellular matrix, hence 
promoting metastasis. 
NGAL expression is regulated by the transcription 
factors: NF-kappaB, CEBP and others [20-24]. Radiation 
and chemotherapy may induce reactive oxygen species 
(ROS) that result in NF-kappaB activation [25,26] and 
subsequent downstream NGAL transcription. In addition, 
the tumor microevironment may alter NF-kappaB 
activity [27]. Chemo- and radiotherapy could result in 
the synthesis of NGAL in cancer cells which may lead 
to the development of therapy-resistant cells. These cells 
can contribute to the reemergence and metastasis of the 
cancer as increased NGAL expression may allow the cells 
to persist under conditions where the therapy-sensitive 
cancer cells could not normally survive.
Cancer cells have increased demands for 
intracellular iron. NGAL is a member of the lipocalin 
family and as such is capable of serving as siderocalins 
or molecules involved in the transport of iron and other 
molecules [28]. Iron is essential for many key processes, 
including the rate-limiting step in DNA synthesis carried 
out by ribonucleotide reductase [29]. Iron (Fe++) is also 
Figure 1: Overview of Potential Effects of NGAL on Cellular Growth. NGAL may serve diverse biochemical functions from 
stabilizing MMP-9 at the cellular membrane in association with CD44 and E-Cadherin (E-Cad), to roles in promoting EMT and invasion. 
In addition, NGAL may have roles in the transport of iron into the cell and influence iron-mediated gene expression. NGAL gene expression 
is infuenced by many transcription figures including NF-κB, p53, and potential hormones such as the estrogen receptor (ER). Iron mediated 
gene expression is complex and can influence the expression of many genes involved in cancer metastasis such as Twist, Slug, and Snail.
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required for cells to progress through the cell cycle from 
G1 to S phase. Tumor cells have a high requirement 
for iron and express elevated levels of the transferrin 
receptor-1 [30-34].  Novel chelators of iron are being 
considered for cancer treatment [35]. Iron chelators, such 
as Desferrioxamine (DFO), inhibit cellular iron transport 
and have been evualated in various cancer clinical trials 
[36]. Oxygen and iron concentrations may be altered in 
the tumor microenvironment due to drastic tumor growth 
[37-40]. In order for a cancer cell to survive, invade, and 
metastasize it may have to have increased iron transport 
as well as elevated glycolysis [11-14,40,41]. The role 
of iron transport in chemotherapeutic drug resistance of 
cancer cells is complex and may depend on the particular 
drug and cancer type investigated [42,43]. Interestingly, 
some iron depletors have been shown to decrease 
resistance of certain cancer cells to chemotherapeutic 
drugs including doxorubicin [44,45].
Increased levels of NGAL have been detected in 
the urine of patients with various types of cancer (i.e. 
brain, breast, colon, ovarian, pancreatic and prostate). 
Novel non-invasive urine-based tests could prove useful 
for the detection and/or prognosis of many cancer types 
[46-49].
The role(s) of NGAL in chemotherapeutic drug 
resistance, invasion, and cancer metastasis are not 
fully elucidated [15]. Targeting NGAL could result in 
decreased cancer cell survival and tumor regression 
as well as improve the effectiveness of radiation and 
chemotherapy in cancer therapy. NGAL is considered 
by some scientists to have properties of an oncogene. It 
has been shown in some studies to increase the mobility, 
invasion, metastasis, and tumorigenesis of certain cancer 
cells [breast, colorectal cancer (CRC)] [50-52]. Elevated 
expression of NGAL increases the invasiveness of certain 
cancer cells, while inhibition of NGAL expression 
decreases their invasiveness and metastasis [17, 19, 50]. 
New approaches to target MMP-9/NGAL are needed as 
MMP-9 inhibitors have not performed well in clinical 
cancer trials [54] and NGAL has functions which are 
independent of MMP-9. 
NGAL may exert many different effects that are 
important in invasion and metastasis. NGAL can stabilize 
MMP-9 at the cell surface [55-57]. This complex may be 
associated with CD44 which may promote the cleavage 
of E-Cadherin (E-Cad) into soluble (s)E-Cad thereby 
promoting EMT [57,58]. A diagram illustrating potential 
effects of NGAL on cell survival is presented in Figure 
1. In the following studies, we examined the effects of 
ectopic NGAL expression on the sensitivity of breast 
cancer and CRC to a common chemotherapeutic drug 
used to treat many cancer patients (doxorubicin, a.k.a 
Adriamycin). We chose to examine the effects of ecotopic 
NGAL expression on sensitivity to doxorubicin on two 
different different types of cancers. Breast cancer which 
is generally sensitive to doxorubicin therapy and CRC 
which is considered resistant to doxorubicin therapy. An 
immortalized breast epithelial cell line, MCF-10A, was 
also examined in these studies.
RESULTS 
Infection of Cell Lines with a Retrovirus 
Encoding NGAL and Expression of Ectopic 
NGAL.
 MCF-10A, MCF-7, and HT-29 cells were infected 
with a retrovirus encoding NGAL or the empty retrovirus 
pLXSN. NGAL was detected in the supernatants from 
NGAL retrovirus infected cells (Figure 2). In contrast, 
NGAL was not detected in the empty vector pLXSN 
virus infected cells.
Effects of Enforced NGAL Expression on 
Sensitivity to Doxorubicin.
 We next examined the effects of elevated 
NGAL expression on the sensitivity of the cell lines 
to doxorubicin using MTT assays. A representative 
MTT assay is presented in Figure 3. Also included 
in these anaylses were the effects of doxorubicin on a 
Figure 2: NGAL Expression in pLXSN and NGAL 
Infected Cells. pLXSN empty vector and NGAL infected 
MCF-10A, MCF-7, and HT-29T were cultured for 24 hours in 
the absence of FBS and then the supernatants were analyzed for 
the expression of NGAL as described in Material & Methods. 
All the experiments in this figure were performed at the same 
time (set up on the same day).
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Figure 3: Doxorubicin IC50 analysis in NGAL and pLXSN Infected Cells and Doxorubicin-Resistant MCF-7/DoxR 
Cells. Cells were collected and seeded (2000 cells/well) in 96 well plates. The following day, serial two-fold dilutions of doxorubicin were 
added to the wells. Four days later, MTT assays were performed to determine the effects of doxorubicin on: Panel A) MCF-10A/pLXSN 
(solid squares), MCF-10A/NGAL (solid triangles), Panel B) MCF-7/pLXSN (solid squares), MCF-7/NGAL (solid triangles) and 25 nM 
doxorubicin selected MCF-7/DoxR cells (solid circles), Panel C) HT-29/pLXSN (solid squares), HT-29/NGAL (solid triangles). A hatched 
horizontal line is present at the 50% relative growth mark from which the IC50 can be calculated. A veritical arrow indicates the IC50. The 
statistical significance was determined by the unpaired t test (***, P<0.001). All the experiments in this figure were performed at the same 
time (set up on the same day). These experiments were repeated multiple times and similar results were obtained.
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doxorubicin-resistant MCF-7 line named MCF-7/DoxR 
(Chappell AER paper in press) that were performed at the 
same time. Clearly, the doxorubicin-resistant MCF-7/DoxR 
is approximately 20-fold more resistant to doxorubicin 
than the MCF-7/pLXSN or MCF-7/NGAL cell lines 
demonstrating that NGAL expression alone does not 
confer doxorubicin resistance in these cells.
The doxorubicin IC50s for various NGAL- and 
pLXSN-infected cell lines representing different tissues 
are presented in Table 1. Increased NGAL expression did 
not significantly (>2-fold) alter the IC50s for doxorubicin 
in the cell lines examined. 
DISCUSSION.  
These studies were undertaken to determine whether 
increased NGAL expression altered the sensitivity to the 
chemotherapeutic drug doxorubicin in cancer cell types 
which are normally sensitive to doxorubicin (breast) 
and cancer cell types which are normally resistant to 
doxorubicin (CRC) as well as immortalized breast 
epithelial cells (MCF-10A) which are not malignant. 
NGAL may have roles in iron transport which may be 
associated with chemoresistance in certain cancers. 
Some studies have shown that iron chelators will reduce 
chemotherapeutic drug resistance [44,45]. However, in 
our studies, elevated NGAL expression did not alter the 
sensitivity to doxorubicin of neither the breast cancer 
nor CRC cells examined. Additionally, it did not alter the 
sensitivity of the immortalized breast epithelial MCF-10A 
cells. Note, it is also conceivable that elevated NGAL 
expression could have made the cells more sensitive to 
doxorubicin, but that did not appear to occur in these cells, 
or other cells examined. 
The doxorubicin resistant MCF-7/DoxR cell line 
was also infected with the retrovirus encoding NGAL 
(Figure 2), however, these cells were not more resistant to 
doxorubicin than empty vector control MCF-7/DoxR cells 
(data not presented). NGAL expression was not detected 
at higher levels in drug resistant MCF-7/DoxR+pLXSN 
cells than MCF-7/pLXSN (Figure 2). Moreover, the 
doxorubicin resistant MCF-7/DoxR cells do not normally 
express NGAL; however, upon treatment with doxorubicin 
increased NGAL protein has been detected [59]. Elevated 
NGAL expression does not appear, by itself, to increase 
the resistance to doxorubicin in the cells examined. Such 
changes could be occurring in the regulation of various 
signaling pathways or drug transporters in these cells.
Although NGAL expression has been associated 
with a poor prognosis in breast and other cancers 
[24,60,61], elevated expression of NGAL does not alter 
the IC50 for the chemotherapeutic drug doxorubicin. 
Furthermore, elevated expression of NGAL did not 
alter the responses of either the CRC line HT-29 or the 
Table 1: Effects of Ectopic NGAL Expression on the 
Doxorubicin IC50 in Cell Lines Derived from Different 
Cancer Types.1
Cell Line Type Doxorubicin IC50
MCF-10A/pLXSN mammary luminal epithelial, non malignant, near diploid 32 nM
MCF-10A/NGAL 30 nM
MCF-7/pLXSN breast cancer ER+, luminal 90 nM
MCF-7/NGAL 80 nM
MCF-7/DoxR doxorubicin resistant MCF-7 2000 nM
HT-27/pLXSN colorectal cancer 40 nM
HT-27/NGAL 40 nM
1MTT analysis was performed with different unselected cancer lines and 
certain 25 nM doxorubicin resistant (DoxR). Determined by plating 5,000 
cells/well in 96 well plates in phenol red free RPMI 1640 + 10% FBS. 
Serial 2-fold dilutions (n=12 dilutions) of doxorubicin were dispensed 
into 8 wells per each doxorubicin concentration after the first day. MTT 
analysis was performed after 4 additional days of incubation and results 
were normalized to untreated cells as described [62].
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immortalized epithelial line MCF-10A to doxorubicin.
MATERIALS & METHODS.
Cell Lines and Growth Factors. 
The breast cancer (MCF-7) and CRC (HT-29) cell 
lines were obtained from the ATCC (Rockville, MD, 
USA). Cells were maintained in a humidified 5% CO2 
incubator at 37°C with RPMI-1640 [(RPMI) Invitrogen, 
Carlsbad, CA, USA] supplemented with 10% fetal bovine 
serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA). 
This complete RPMI media is abbreviated cRPMI. The 
immortalized breast epithelial MCF-10A line was obtained 
from the ATCC and cultured in DMEM/F12 (Invitrogen) 
medium containing: 2.5mM L-glutamine, supplemented 
with 5% heat inactivated equine serum (Invitrogen), 
500 ng/ml hydrocortisone (Sigma-Aldrich), 21.5 ng/ml 
epidermal growth factor (EGF) (Sigma-Aldrich), 10 μg/ml 
insulin (Sigma-Aldrich), 100 ng/ml cholera toxin (Sigma-
Aldrich), and 15mM HEPES (Sigma-Aldrich).
Methylthiazol Tetrazolium Assay.
Methylthiazol tetrazolium (MTT) assays were 
performed to determine a cell line’s sensitivity to 
chemotherapeutic drugs. 2 x 103 cells per well were 
plated in 96-well plates in 100 μL of cRPMI without 
phenol red (Invitrogen™, Carlsbad, CA) and allowed to 
attach overnight under normal culture conditions. The 
next day, serial two-fold dilutions of a chemotherapeutic 
drug were made and 100 μL of each dilution were 
added to a corresponding well on the 96-well plate. 
Cells were incubated for four days under normal culture 
conditions. On the fourth day, 22.2 μL of a 5 mg/mL 
solution of thiazolyl blue tetrazolium bromide (Sigma-
Aldrich, Saint Louis, MO) in 1X PBS was added to each 
well and incubated for 90 minutes at 37°C. The media 
was then removed and 150 μL of dimethyl sulfoxide 
(DMSO) (Fisher Scientific, Pittsburgh, PA) was added 
to resuspend formazin crystals to produce a purple 
color which was subsequently read on a Multiskan EX 
Microplate photometer (Thermo Scientific, Hudson, 
NH) at a wavelength of 570 nm. Colormetric readings 
were normalized against plates of non-treated cells 
under identical culture conditions. Relative growth was 
calculated by dividing normalized cell growth values in 
the presence of drugs by normalized cell growth values in 
the absence of drugs and the results were graphed. Drug 
concentrations that killed at least 50% of the cells (IC50) 
were determined from the calculated graphed values [62]. 
Construction of Retroviral Vector Containing 
NGAL. 
The pLXSN/NGAL retroviral expression vector 
(referred to here and throughout this study as NGAL) was 
constructed using the retroviral vector pLXSN (Clontech©, 
Mountain View, CA) as the backbone. The full length 
cDNA of human NGAL (Lcn2, GenBank accession no. 
BC033089) was amplified from the pcDNA3.1(+)-NGAL 
plasmid [51] using specific primers for regions flanking 
either ends of the gene insert. The PCR product was then 
inserted into a pCR2.1-TOPOR TA vector (Invitrogen™, 
Carlsbad, CA), subsequently digested with EcoRI 
endonuclease (New England Biolabs®, Ipswich, MA), and 
the resulting gene fragment was ligated into the EcoRI 
digested pLXSN vector. 
Packaging of Retroviral Vectors.
Packaging of the retroviral vectors used in this 
study was as follows. 10 mL of a 0.1 % gelatin/sterile 
water solution (Specialty Media, Chemicon/Millipore™, 
Billerica, MA) was used to gelatin coat Corning 75 cm2 
flasks (Corning, NY) for one hour at room temperature 
and then removed. Following two subsequent washes 
with 1X phosphate buffered saline (PBS) (110 mM 
NaCl, 2.1 mM KCl, 1.1 mM KH2PO4, 6.7 mM Na3PO4, 
pH 7.4), 6 x 106 total 293T cells were plated in 10 mL 
cDMEM and allowed to adhere at 370C overnight to the 
gelatin coated flasks. The next day, the culture media 
was removed and replaced with 10 mL fresh cDMEM 
one hour prior to transfection. DNA calcium phosphate 
precipitation was used to transfect 293T cells. 15 μg of 
the packaging vector pCL-Ampho (Imgenex©, San Diego, 
CA) was mixed with 35 μg of pLXSN/NGAL, in 1.5 mL 
of 0.25 M CaCl2. This mixture was then added drop wise 
to 1.5 mL of 2X HBS (50 mM HEPES, 280 mM NaCl2, 
1.5 mM Na2HPO4, pH 7.17) and allowed to precipitate 
at room temperature for 45 minutes. After the precipitate 
incubation time, the solution of calcium-phosphate/DNA 
was added to the T75 flask of 293T cells and incubated 
for six hours at 37°C in a humidified incubator with 5% 
CO2. Media was then removed and replaced with 9 mL 
of a 15% glycerol/PBS solution for one minute at room 
temperature. This solution was then removed and the cells 
gently washed once with 1X PBS before adding back 
10 mL of fresh cDMEM. Spent media containing the 
packaged virus particles were harvested 48 and 72 hours 
later. The viral supernatant was filtered through a 0.45 μm 
PVDF filter (Millipore™,Billerica, MA) to remove cellular 
debris, aliquoted, and used fresh for subsequent retroviral 
transductions or stored frozen at -80°C for later use. The 
viral supernatants were used to infected the various cell 
lines and stable transformed pools or either NGAL or 
pLXSN (empty vector control) were selected in media 
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contain 2 mg/ml G418 (Geneticin®, Sigma-Aldrich) after 
2-3 weeks of section. Medium was changed every 3 days 
with fresh medium containing 2 mg/ml G418.
Detection of Secreted NGAL
Supernatant lysates used to determine the levels 
of NGAL protein in the supernatant were harvested and 
prepared as follows. All cell lines were plated in 6-well 
plates and cultured under normal culture conditions in 
cRPMI. Once the cells reached 80% confluency the media 
were removed, the cells were washed twice with 1X PBS, 
and 2 mL of fresh RPMI without FBS was added back. 
After 24 hours, the supernatants were harvested, cleared 
of cellular debris via centrifugation, and processed. Total 
protein from the collected supernatants was isolated by 
mixing 1 mL of the sample with 250 μL of 100% (w/v) 
trichloroacetic acid (TCA) (Sigma-Aldridge, Saint Louis, 
MO) and incubating the mixture at 4°C for 15 minutes. 
The sample pellets were collected via centrifugation at 
14000 RPM for 15 minutes. The pellets were washed 
twice with ice cold 100% acetone and allowed to air dry. 
The protein pellets were resuspended in 25 μL of western 
sample buffer, boiled for 5 minutes, and examined by 
western blot analysis.
20 μL of the prepared supernatant samples was 
separated on 12% Tris-glycine poly-acrylamide gels and 
transferred to polyvinylidene fluoride (PVDF) membranes 
(Thermo Scientific, Rockford, IL). All membranes were 
blocked in 1X Tris-buffered saline + Tween-20 (TBST) 
(32 mM Tris, 125 mM NaCl, 0.5% Tween-20, pH 8) 
containing 1% bovine serum albumin (BSA) (Fisher/
Thermo Scientific, Rockford, IL) overnight at 4°C with 
gently shaking. Blocked membranes were placed in 
appropriate dilutions of the NGAL antibody [50] in 1x 
TBST + 1% BSA overnight at 4°C with gentle shaking. 
The next day, membranes were washed four times with 1X 
TBST before adding the appropriate secondary antibody 
made up in 1X TBST plus 5% non-fat dry milk for one 
hour. After another round of four washes, the membranes 
were treated with horseradish peroxidase enhanced 
chemiluminescence (Pierce/Thermo Scientific, Rockford, 
IL) as per manufacturer’s instructions and protein bands 
visualized via exposure to X-ray film (Research Products 
42 International, Mount Prospect, IL). 0.1% coomassie 
brilliant blue R250 (CBB) (Sigma-Aldrich) in a 50% 
methanol/7% acetic acid solution was used to stain total 
protein on the cellular supernatant immunoblots as a 
loading control.
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